Mirum Pharmaceuticals

Stories

Vir's hepatitis D combination succeeds in first Phase 3 trial

Reported Phase 3 success in September 2026 for an acquired hepatitis D drug

Hepatitis D only infects people who already have hepatitis B, and it is the more aggressive of the two. Until this year, the United States had no approved drug for it. On November 8, Vir Biotechnology reported that a two-drug combination cleared detectable virus and normalized levels of alanine aminotransferase, a liver enzyme, in 44% of patients after 48 weeks.

Updated 2 days ago

First potential therapy for primary sclerosing cholangitis clears Phase 2b

New Capabilities

As of May 2026: Sponsor of volixibat; targeting NDA filing in 2H 2026

For the roughly 30,000 Americans living with primary sclerosing cholangitis (PSC), the U.S. Food and Drug Administration has never approved a single drug. On May 4, 2026, Mirum Pharmaceuticals reported that its experimental pill volixibat hit the primary endpoint of its Phase 2b VISTAS trial, reducing the relentless itch far more than placebo.

Updated May 31